Global Human Plasma-derived Hyperimmune Product Supply, Demand and Key Producers, 2023-2029

1 Supply Summary

• 1.1 Human Plasma-derived Hyperimmune Product Introduction
• 1.2 World Human Plasma-derived Hyperimmune Product Supply & Forecast
  • 1.2.1 World Human Plasma-derived Hyperimmune Product Production Value (2018 & 2022 & 2029)
  • 1.2.2 World Human Plasma-derived Hyperimmune Product Production (2018-2029)
  • 1.2.3 World Human Plasma-derived Hyperimmune Product Pricing Trends (2018-2029)
• 1.3 World Human Plasma-derived Hyperimmune Product Production by Region (Based on Production Site)
  • 1.3.1 World Human Plasma-derived Hyperimmune Product Production Value by Region (2018-2029)
  • 1.3.2 World Human Plasma-derived Hyperimmune Product Production by Region (2018-2029)
  • 1.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Region (2018-2029)
  • 1.3.4 North America Human Plasma-derived Hyperimmune Product Production (2018-2029)
  • 1.3.5 Europe Human Plasma-derived Hyperimmune Product Production (2018-2029)
  • 1.3.6 China Human Plasma-derived Hyperimmune Product Production (2018-2029)
  • 1.3.7 Japan Human Plasma-derived Hyperimmune Product Production (2018-2029)
• 1.4 Market Drivers, Restraints and Trends
  • 1.4.1 Human Plasma-derived Hyperimmune Product Market Drivers
  • 1.4.2 Factors Affecting Demand
  • 1.4.3 Human Plasma-derived Hyperimmune Product Major Market Trends
• 1.5 Influence of COVID-19 and Russia-Ukraine War
  • 1.5.1 Influence of COVID-19
  • 1.5.2 Influence of Russia-Ukraine War

2 Demand Summary

• 2.1 World Human Plasma-derived Hyperimmune Product Demand (2018-2029)
• 2.2 World Human Plasma-derived Hyperimmune Product Consumption by Region
  • 2.2.1 World Human Plasma-derived Hyperimmune Product Consumption by Region (2018-2023)
  • 2.2.2 World Human Plasma-derived Hyperimmune Product Consumption Forecast by Region (2024-2029)
• 2.3 United States Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.4 China Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.5 Europe Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.6 Japan Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.7 South Korea Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.8 ASEAN Human Plasma-derived Hyperimmune Product Consumption (2018-2029)
• 2.9 India Human Plasma-derived Hyperimmune Product Consumption (2018-2029)

3 World Human Plasma-derived Hyperimmune Product Manufacturers Competitive Analysis

• 3.1 World Human Plasma-derived Hyperimmune Product Production Value by Manufacturer (2018-2023)
• 3.2 World Human Plasma-derived Hyperimmune Product Production by Manufacturer (2018-2023)
• 3.3 World Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2018-2023)
• 3.4 Human Plasma-derived Hyperimmune Product Company Evaluation Quadrant
• 3.5 Industry Rank and Concentration Rate (CR)
  • 3.5.1 Global Human Plasma-derived Hyperimmune Product Industry Rank of Major Manufacturers
  • 3.5.2 Global Concentration Ratios (CR4) for Human Plasma-derived Hyperimmune Product in 2022
  • 3.5.3 Global Concentration Ratios (CR8) for Human Plasma-derived Hyperimmune Product in 2022
• 3.6 Human Plasma-derived Hyperimmune Product Market: Overall Company Footprint Analysis
  • 3.6.1 Human Plasma-derived Hyperimmune Product Market: Region Footprint
  • 3.6.2 Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
  • 3.6.3 Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
• 3.7 Competitive Environment
  • 3.7.1 Historical Structure of the Industry
  • 3.7.2 Barriers of Market Entry
  • 3.7.3 Factors of Competition
• 3.8 New Entrant and Capacity Expansion Plans
• 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World

• 4.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Comparison
  • 4.1.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Comparison (2018 & 2022 & 2029)
  • 4.1.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Value Market Share Comparison (2018 & 2022 & 2029)
• 4.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Comparison
  • 4.2.1 United States VS China: Human Plasma-derived Hyperimmune Product Production Comparison (2018 & 2022 & 2029)
  • 4.2.2 United States VS China: Human Plasma-derived Hyperimmune Product Production Market Share Comparison (2018 & 2022 & 2029)
• 4.3 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Comparison
  • 4.3.1 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Comparison (2018 & 2022 & 2029)
  • 4.3.2 United States VS China: Human Plasma-derived Hyperimmune Product Consumption Market Share Comparison (2018 & 2022 & 2029)
• 4.4 United States Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share, 2018-2023
  • 4.4.1 United States Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (States, Country)
  • 4.4.2 United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2018-2023)
  • 4.4.3 United States Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2018-2023)
• 4.5 China Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share
  • 4.5.1 China Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (Province, Country)
  • 4.5.2 China Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2018-2023)
  • 4.5.3 China Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2018-2023)
• 4.6 Rest of World Based Human Plasma-derived Hyperimmune Product Manufacturers and Market Share, 2018-2023
  • 4.6.1 Rest of World Based Human Plasma-derived Hyperimmune Product Manufacturers, Headquarters and Production Site (State, Country)
  • 4.6.2 Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production Value (2018-2023)
  • 4.6.3 Rest of World Based Manufacturers Human Plasma-derived Hyperimmune Product Production (2018-2023)

5 Market Analysis by Type

• 5.1 World Human Plasma-derived Hyperimmune Product Market Size Overview by Type: 2018 VS 2022 VS 2029
• 5.2 Segment Introduction by Type
  • 5.2.1 Hepatitis B Immunoglobulins
  • 5.2.2 Rabies Immunoglobulins
  • 5.2.3 Tetanus Immunoglobulins
  • 5.2.4 Rho(D) Immunoglobulins
  • 5.2.5 Other
• 5.3 Market Segment by Type
  • 5.3.1 World Human Plasma-derived Hyperimmune Product Production by Type (2018-2029)
  • 5.3.2 World Human Plasma-derived Hyperimmune Product Production Value by Type (2018-2029)
  • 5.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Type (2018-2029)

6 Market Analysis by Application

• 6.1 World Human Plasma-derived Hyperimmune Product Market Size Overview by Application: 2018 VS 2022 VS 2029
• 6.2 Segment Introduction by Application
  • 6.2.1 Government Institution
  • 6.2.2 Private Sector
  • 6.2.3 Others
• 6.3 Market Segment by Application
  • 6.3.1 World Human Plasma-derived Hyperimmune Product Production by Application (2018-2029)
  • 6.3.2 World Human Plasma-derived Hyperimmune Product Production Value by Application (2018-2029)
  • 6.3.3 World Human Plasma-derived Hyperimmune Product Average Price by Application (2018-2029)

7 Company Profiles

• 7.1 CSL Behring
  • 7.1.1 CSL Behring Details
  • 7.1.2 CSL Behring Major Business
  • 7.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
  • 7.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.1.5 CSL Behring Recent Developments/Updates
  • 7.1.6 CSL Behring Competitive Strengths & Weaknesses
• 7.2 Grifols
  • 7.2.1 Grifols Details
  • 7.2.2 Grifols Major Business
  • 7.2.3 Grifols Human Plasma-derived Hyperimmune Product Product and Services
  • 7.2.4 Grifols Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.2.5 Grifols Recent Developments/Updates
  • 7.2.6 Grifols Competitive Strengths & Weaknesses
• 7.3 Biotest
  • 7.3.1 Biotest Details
  • 7.3.2 Biotest Major Business
  • 7.3.3 Biotest Human Plasma-derived Hyperimmune Product Product and Services
  • 7.3.4 Biotest Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.3.5 Biotest Recent Developments/Updates
  • 7.3.6 Biotest Competitive Strengths & Weaknesses
• 7.4 Kedrion
  • 7.4.1 Kedrion Details
  • 7.4.2 Kedrion Major Business
  • 7.4.3 Kedrion Human Plasma-derived Hyperimmune Product Product and Services
  • 7.4.4 Kedrion Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.4.5 Kedrion Recent Developments/Updates
  • 7.4.6 Kedrion Competitive Strengths & Weaknesses
• 7.5 CBPO
  • 7.5.1 CBPO Details
  • 7.5.2 CBPO Major Business
  • 7.5.3 CBPO Human Plasma-derived Hyperimmune Product Product and Services
  • 7.5.4 CBPO Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.5.5 CBPO Recent Developments/Updates
  • 7.5.6 CBPO Competitive Strengths & Weaknesses
• 7.6 Emergent (Cangene)
  • 7.6.1 Emergent (Cangene) Details
  • 7.6.2 Emergent (Cangene) Major Business
  • 7.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
  • 7.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.6.5 Emergent (Cangene) Recent Developments/Updates
  • 7.6.6 Emergent (Cangene) Competitive Strengths & Weaknesses
• 7.7 Kamada
  • 7.7.1 Kamada Details
  • 7.7.2 Kamada Major Business
  • 7.7.3 Kamada Human Plasma-derived Hyperimmune Product Product and Services
  • 7.7.4 Kamada Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.7.5 Kamada Recent Developments/Updates
  • 7.7.6 Kamada Competitive Strengths & Weaknesses
• 7.8 CNBG
  • 7.8.1 CNBG Details
  • 7.8.2 CNBG Major Business
  • 7.8.3 CNBG Human Plasma-derived Hyperimmune Product Product and Services
  • 7.8.4 CNBG Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.8.5 CNBG Recent Developments/Updates
  • 7.8.6 CNBG Competitive Strengths & Weaknesses
• 7.9 Hualan Bio
  • 7.9.1 Hualan Bio Details
  • 7.9.2 Hualan Bio Major Business
  • 7.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
  • 7.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.9.5 Hualan Bio Recent Developments/Updates
  • 7.9.6 Hualan Bio Competitive Strengths & Weaknesses
• 7.10 Shanghai RAAS
  • 7.10.1 Shanghai RAAS Details
  • 7.10.2 Shanghai RAAS Major Business
  • 7.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
  • 7.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.10.5 Shanghai RAAS Recent Developments/Updates
  • 7.10.6 Shanghai RAAS Competitive Strengths & Weaknesses
• 7.11 Sichuan Yuanda Shuyang
  • 7.11.1 Sichuan Yuanda Shuyang Details
  • 7.11.2 Sichuan Yuanda Shuyang Major Business
  • 7.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
  • 7.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
  • 7.11.6 Sichuan Yuanda Shuyang Competitive Strengths & Weaknesses
• 7.12 ADMA Biologics
  • 7.12.1 ADMA Biologics Details
  • 7.12.2 ADMA Biologics Major Business
  • 7.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
  • 7.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Production, Price, Value, Gross Margin and Market Share (2018-2023)
  • 7.12.5 ADMA Biologics Recent Developments/Updates
  • 7.12.6 ADMA Biologics Competitive Strengths & Weaknesses

8 Industry Chain Analysis

• 8.1 Human Plasma-derived Hyperimmune Product Industry Chain
• 8.2 Human Plasma-derived Hyperimmune Product Upstream Analysis
  • 8.2.1 Human Plasma-derived Hyperimmune Product Core Raw Materials
  • 8.2.2 Main Manufacturers of Human Plasma-derived Hyperimmune Product Core Raw Materials
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis
• 8.5 Human Plasma-derived Hyperimmune Product Production Mode
• 8.6 Human Plasma-derived Hyperimmune Product Procurement Model
• 8.7 Human Plasma-derived Hyperimmune Product Industry Sales Model and Sales Channels
  • 8.7.1 Human Plasma-derived Hyperimmune Product Sales Model
  • 8.7.2 Human Plasma-derived Hyperimmune Product Typical Customers

9 Research Findings and Conclusion

10 Appendix

• 10.1 Methodology
• 10.2 Research Process and Data Source